

Bod Australia Reinstated to Official Quotation

Sydney, Australia – 8 December 2017: Developer and distributor of natural, evidence-based cosmetics and natural medicines, Bod Australia Limited (“Bod” or the “Company”) (ASX: BDA) is pleased to advise that the Company’s securities have been reinstated to official quotation following a decision by the ASX in relation to the application of chapter 11 of the ASX Listing Rules.

Following the provision of relevant information to the ASX, it has been determined that Bod’s current medicinal cannabis activities do not constitute a change to the nature or scale of the activities of the Company.

For more information: bodaustralia.com

- ENDS -

About Bod Australia

Bod Australia Limited operates a cosmetics and natural medicines business focused on all natural, evidence based products. In the cosmetics segment Bod has exclusive rights to distribute Pommade Divine in Australia, New Zealand and the export market to China, and BIOEFFECT in Australia and New Zealand. Bod is also developing a range of natural medicines, having recently commenced sales of Pinpoint, for memory and concentration, and natural anti-inflammatory Flexofytol. Led by an experienced sales team which includes ex-Bellamy’s sales representatives, the Company is focused on the distribution of these brands and intends to develop new products across baby skin care and additional natural remedies targeting menopause and sinusitis. Bod has also signed a supply agreement with Swiss botanical extracts manufacturer Linnea Natural Pharma Solutions to develop skin care and therapeutic products using standardised, GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538